Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate.

[1] Preliminary data has been reported in 2013 from an early stage clinical trial in combination with Lenalidomide and Dexamethasone.

[1] Follow up data reported "encouraging efficacy" in December 2014.

[2] As of December 2014[update], it is in clinical trials for triple negative metastatic breast cancer and metastatic urinary bladder cancer.

[2] CD138 (Syndecan-1) is highly overexpressed on various solid tumors and in hematological malignancies, and represents one of the most specific target antigens for identification of multiple myeloma (MM) cells.